 |
Camomile
tea and diabetes |
| |
Although this study provides an insight into the effects of camomile and its
components on rats and cells in the laboratory, the extrapolation
of these findings to humans is very premature. (Behind the Headlines
- NHS Choices, UK) |
| |
|
|
Safety
and efficacy of premixed insulin analogues in type 2 diabetes |
| |
This systematic review compared the evidence
for premixed insulin analogues (a mixture of rapid-acting and intermediate-acting
insulin analogues) with other antidiabetic agents in adults with
type 2 diabetes (National Electronic Library for Medicines, UK) |
| |
|
|
Diabetes
type 2: overthrow the blood-sugar dictator |
| |
A new drug can improve treatment by increasing
insulin sensivity and helping patients to lose weight (Times, UK) |
| |
|
|
Exeter
Diabetes Handbook - Integrated diabetic footcare pathway |
| |
The Exeter Diabetic Footcare Service undertook
a randomised controlled trial in 1997 to evaluate an integrated
care pathway (ICP), aimed at improving the identification and management
of the high-risk diabetic foot (NDST, UK) |
| |
|
|
Inhaled
human insulin findings varied |
| |
Two-year treatment with inhaled human insulin
showed a small nonprogressive difference in forced expiratory volume
in 1 second and comparable sustained HbA1c improvement when compared
with subcutaneous insulin in adults with type 2 diabetes, according
to the findings of a recent trial (Endocrine Today) |
| |
|
|
Oramed
Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary
Drug Delivery Platform |
| |
Oramed Pharmaceuticals, Inc., a developer of
oral drug delivery systems, announced today that it has launched
pre-clinical trials of ORMD 0901, a GLP1-analog. ORMD 0901 belongs
to the Incretin family of drugs which helps to manage diabetes,
including reduction in blood glucose levels and inhibiting glucagon
secretion (Oramed Pharmaceuticals, Israel) |
| |
|
|
The
EU Platform on Diet, Physical Activity and Health |
| |
Third Monitoring Progress Report (RAND) |
| |
|
|
Daily
blood glucose profiles of glibenclamide and gliclazide taken
once or twice daily in elderly type 2 diabetic patients |
| |
These results suggest that the blood glucose-lowering
effects of a once- and twice-daily moderate daily dose of glibenclamide
or gliclazide do not differ in elderly type 2 diabetic patients.
However, glibenclamide, regardless of the dosage schedule, tends
to lower the plasma glucose values between midnight and early morning
(Geriatrics and Gerontology International) |
| |
|
|
Type
2 Diabetes Patients Treated With Dapagliflozin Show Dose-Dependent
Glycaemic Changes |
| |
Use of dapagliflozin in patients with type 2
diabetes appears to have a dose-dependent effect on levels of glycosylated
haemoglobin (Hb A1C) and fasting plasma glucose (FPG) levels, researchers
reported here at the American College of Clinical Pharmacology
(ACCP) 37th Annual meeting (Doctors Guide) |
| |
|
